Image For Activity Cover
Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA: The EDIT-CMD Randomized Clinical Trial - JIMG August 2022
Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA: The EDIT-CMD Randomized Clinical Trial - JIMG August 2022

This first performed randomized, placebo-controlled trial in patients with ANOCA showed that 6 weeks of therapy with diltiazem, when compared with placebo, did not substantially improve CVDys, symptoms, or quality of life, but diltiazem therapy did reduce prevalence of epicardial spasm.

Editors

Editor-in-Chief
Y.S. Chandrashekhar, MD, DM, FACC

CME Editor
Ragavendra R. Baliga, MD

Author
Gbemiga G. Sofowora, MBChB, FACC

Important Dates

Date of Release: August 1, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: July 31, 2023

Summary
Availability: On-Demand
Expires on Jul 31, 2023
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By